This response was inhibited by imatinib mesylate, a receptor tyrosine kinase inhibitor currently under investigation as an anti-proliferation treatment of PAH (P < 0.05; Fig. 2e). This evidence concerns the gene NTRK1 and pulmonary arterial hypertension.